NCT01506375View on ClinicalTrials.gov

Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions
Hay Fever
Interventions
BIOLOGICAL

gpASIT+TM

1 subcutaneous injection every 7 days during 29 days

BIOLOGICAL

gpASIT+TM + adjuvant

1 subcutaneous injection every 7 days during 29 days

Trial Locations (1)

3000

Universitaire Ziekenhuis van Leuven, Leuven

Sponsors

Lead Sponsor

BioTech Tools S.A.
All Listed Sponsors
lead

BioTech Tools S.A.

INDUSTRY

NCT01506375 - Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant | Biotech Hunter | Biotech Hunter